Nuvation Bio Inc. Operating Lease Cost
Nuvation Bio Inc. (NUVB) reported Operating Lease Cost of $1.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- Nuvation Bio Inc. operating lease, cost for the quarter ending 2026-06-30 was $1.20M, a 14.29% decline year-over-year.
- Nuvation Bio Inc. operating lease, cost for the quarter ending 2026-03-31 was $600.00K, a 14.29% decline year-over-year.
- Nuvation Bio Inc. operating lease, cost for the quarter ending 2025-12-31 was $500.00K, a 16.67% decline year-over-year.
- Nuvation Bio Inc. operating lease, cost for the quarter ending 2025-09-30 was $2.00M, a 0.00% change year-over-year.
- Nuvation Bio Inc. operating lease, cost for fiscal 2025 was $2.50M, a 3.85% decline from fiscal 2024.
- Nuvation Bio Inc. operating lease, cost for fiscal 2024 was $2.60M, a 52.94% increase from fiscal 2023.
- Nuvation Bio Inc. operating lease, cost for fiscal 2023 was $1.70M, a 41.67% increase from fiscal 2022.
- Nuvation Bio Inc. operating lease, cost for fiscal 2022 was $1.20M, a 0.00% change from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.20M 10-Q · filed 2026-08-06 | $1.20M 10-Q · filed 2026-08-06 | $2.30M derived: sum of 3 quarters · filed 2026-08-06 | $4.30M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $600.00K 10-Q · filed 2026-05-04 | $1.10M derived: sum of 2 quarters · filed 2026-05-04 | $3.10M derived: sum of 3 quarters · filed 2026-05-04 | $4.50M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.50M derived: sum of 2 quarters · filed 2026-03-02 | $3.90M derived: sum of 3 quarters · filed 2026-08-06 | $2.50M 10-K · filed 2026-03-02 | ||
| 2025-09-30 | $2.00M 10-Q · filed 2025-11-03 | $3.40M derived: sum of 2 quarters · filed 2026-08-06 | $2.00M 10-Q · filed 2025-11-03 | $4.70M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $1.40M 10-Q · filed 2026-08-06 | $1.40M 10-Q · filed 2026-08-06 | $2.70M derived: sum of 3 quarters · filed 2026-08-06 | $4.70M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $700.00K 10-Q · filed 2026-05-04 | $1.30M derived: sum of 2 quarters · filed 2026-05-04 | $3.30M derived: sum of 3 quarters · filed 2026-05-04 | $4.40M derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.60M derived: sum of 2 quarters · filed 2026-03-02 | $3.70M derived: sum of 3 quarters · filed 2026-03-02 | $2.60M 10-K · filed 2026-03-02 | ||
| 2024-09-30 | $2.00M 10-Q · filed 2025-11-03 | $3.10M derived: sum of 2 quarters · filed 2025-11-03 | $2.00M 10-Q · filed 2025-11-03 | $4.10M derived: sum of 4 quarters · filed 2025-11-03 | ||
| 2024-06-30 | $1.10M 10-Q · filed 2025-08-07 | $1.10M 10-Q · filed 2025-08-07 | $2.10M derived: sum of 3 quarters · filed 2025-08-07 | $3.30M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $500.00K 10-Q · filed 2025-05-07 | $1.00M derived: sum of 2 quarters · filed 2025-05-07 | $2.20M derived: sum of 3 quarters · filed 2025-05-07 | $2.90M derived: sum of 4 quarters · filed 2025-05-07 | ||
| 2023-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.70M derived: sum of 2 quarters · filed 2025-03-06 | $2.40M derived: sum of 3 quarters · filed 2025-03-06 | $1.70M 10-K · filed 2025-03-06 | ||
| 2023-09-30 | $1.20M 10-Q · filed 2024-11-06 | $500.00K 10-Q · filed 2023-11-02 | $1.90M derived: sum of 2 quarters · filed 2024-11-06 | $1.20M 10-Q · filed 2024-11-06 | $2.50M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $700.00K 10-Q · filed 2024-08-05 | $400.00K 10-Q · filed 2023-08-03 | $700.00K 10-Q · filed 2024-08-05 | $1.30M derived: sum of 3 quarters · filed 2024-08-05 | $1.60M derived: sum of 4 quarters · filed 2024-08-05 | |
| 2023-03-31 | $300.00K 10-Q · filed 2024-05-14 | $600.00K derived: sum of 2 quarters · filed 2024-05-14 | $900.00K derived: sum of 3 quarters · filed 2024-05-14 | $1.20M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $600.00K derived: sum of 2 quarters · filed 2024-02-29 | $900.00K derived: sum of 3 quarters · filed 2024-02-29 | $1.20M 10-K · filed 2024-02-29 | ||
| 2022-09-30 | $300.00K 10-Q · filed 2023-11-02 | $600.00K derived: sum of 2 quarters · filed 2023-11-02 | $900.00K 10-Q · filed 2023-11-02 | $1.20M derived: sum of 4 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $300.00K 10-Q · filed 2023-08-03 | $300.00 10-Q · filed 2022-08-04 | $600.00K 10-Q · filed 2023-08-03 | $600.00 10-Q · filed 2022-08-04 | $900.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.20M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $300.00K 10-Q · filed 2023-05-04 | $600.00K derived: sum of 2 quarters · filed 2023-05-04 | $900.00K derived: sum of 3 quarters · filed 2023-05-04 | $900.30K derived: sum of 4 quarters · filed 2023-05-04 | ||
| 2021-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $600.00K derived: sum of 2 quarters · filed 2023-03-15 | $600.30K derived: sum of 3 quarters · filed 2023-03-15 | $1.20M 10-K · filed 2023-03-15 | ||
| 2021-09-30 | $300.00K 10-Q · filed 2022-11-03 | $300.30K derived: sum of 2 quarters · filed 2022-11-03 | $900.00K 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $300.00 10-Q · filed 2022-08-04 | $600.00 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | $300.00K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |